Cepheid GmbH develops, manufactures, distributes and markets fully integrated systems and tests, in particular medical instruments and reagents, for the clinical market as well as applications in the biothreat and industrial sectors. The product portfolio includes diagnostic platforms and associated tests (including GeneXpert, Infinity and Xpert tests) with more than 34 different diagnostic tests as of December 31, 2024; research and development are mainly conducted at Cepheid Inc. in Sunnyvale (USA), and production takes place in Sunnyvale and Solna (Sweden). Distribution is focused on Germany, Austria and Poland and targets hospitals, university clinics, private laboratories and office-based physicians; the company is part of the Danaher group.
Die Entwicklung, die Herstellung, der Vertrieb und Vermarktung von voll-integrierten Systemen und Tests, insbesondere medizinischen Instrumenten und Reagenzien, für den klinischen Markt und zur Anwendung im Biothreat-Markt und in der Industrie.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) Krefeld Local Court, HRB 18104 (as of 9 October 2026)
Source: German Commercial Register (Handelsregister) Krefeld Local Court, HRB 18104 (as of 9 October 2026)
Source: German Commercial Register (Handelsregister) Krefeld Local Court, HRB 18104 (as of 9 October 2026)
Sign in to download data
Source: German Commercial Register (Handelsregister) Krefeld Local Court, HRB 18104 (as of 9 October 2026)
PISM-Medical GmbH
Ehringshausen · Herstellung von pharmazeutischen Spezialitäten und sonstigen pharmazeutischen Erzeugnissen
Wiewelhove Gesellschaft mit beschränkter Haftung
Ibbenbüren · Herstellung von pharmazeutischen Spezialitäten und sonstigen pharmazeutischen Erzeugnissen
Basics GmbH
Leverkusen · Herstellung von pharmazeutischen Spezialitäten und sonstigen pharmazeutischen Erzeugnissen
Sign in to view detailed salary and cost trends.
Sign in to view funding data
Last Round
€12.8M
Series B · Mar 2025
Total
4
Rounds
7
Investors
